68例难治性心力衰竭的治疗体会
摘要
随着心血管疾病的发病逐年增高，难治性心力衰竭的发病也越来越常见。针对患者的具体情况，合理选用内科治疗策略，可以取得较好的疗效，延长患者的生存率及生存时间，改善患者的生活质量。
出处
《现代医药卫生》
2009年第16期2472-2473,共2页
Journal of Modern Medicine & Health
二级参考文献41
-
1[1]Macdonald PS,Hill J,Krum H.COLA Ⅱ Investigators.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
-
2[2]Dobre D,van Veldhuisen DJ.SENIORS Investigators.Tolerability and dose-related effects of nebivolol in elderly patients with heart failure:data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial[J].Am Heart J,2007,154 (1):109-115.
-
3[3]Willenheimer R,van Veldhuisen DJ,CIBIS Ⅲ Investigators.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ.Circulation,2005,112(16):2426-2435.
-
4[4]Chuen M J,MacFadyen RJ.Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure[J].Am J Cardiol,2006,98(10):1416-1417.
-
5[5]Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297 (12):1332-1343.
-
6[6]Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331.
-
7[7]Cleland JG,Coletta AP,Clark AL.Clinical trials update from the American College of Cardiology 2007:ALPHA,EVEREST,FUSION Ⅱ,VALIDD,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP for the evaluation of dyspnoea and THIS-diet[J].Eur J Heart Fail,2007,9(6-7):740-745.
-
8[8]Go AS,Lee WY,Yang J,et al.Statin therapy and risks for death and hospitalization in chronic heart failure[J].JAMA.2006,296(17):2105-2111.
-
9[9]Flevari P,Parissis JT,Leftheriotis D,et al.Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy[J].Am J Cardiol,2006,98(12):1641-1645.
-
10[10]Staessen JA,Li Y,Richart T.Oral renin inhibitors[J].Lancet,2006,368(9545):1449-1456.
共引文献20
-
1王健.哲学思维在心内科临床教学中的应用[J].继续医学教育,2012,26(5):33-36. 被引量：4
-
2陈才顺.慢性充血性心力衰竭诊断与治疗研究进展[J].中国医学文摘（内科学）,2006,27(4):331-333. 被引量：4
-
3王秋娟.倍他乐克治疗慢性稳定性心力衰竭的临床观察[J].中国误诊学杂志,2009,9(15):3580-3581.
-
4周雷.慢性心力衰竭236例治疗体会[J].内科,2009,4(3):392-394. 被引量：4
-
5周雷.236例慢性心力衰竭的治疗体会[J].现代医药卫生,2009,25(15):2344-2345.
-
6杨坚,罗树云.缬沙坦联合卡维地洛治疗慢性充血性心力衰竭[J].中西医结合心脑血管病杂志,2010,8(3):282-283. 被引量：8
-
7王会玖.缬沙坦联合卡维地洛治疗慢性心力衰竭的临床研究[J].中国药房,2011,22(4):348-350. 被引量：17
-
8李卫红.卡维地洛联合缬沙坦治疗慢性心力衰竭临床效果及安全性探究[J].中国医药指南,2012,10(10):134-136. 被引量：11
-
9王熙智.卡维地洛与缬沙坦联用治疗慢性心力衰竭临床研究[J].中国实用医药,2012,7(7):18-19. 被引量：7
-
10罗艳春.螺内酯在老年高血压并发舒张性心力衰竭的应用研究[J].实用心脑肺血管病杂志,2012,20(6):1046-1047. 被引量：3
-
1夏增胜,马建军,赵辉.难治性心力衰竭伴低渗性脑病(附12例分析)[J].中国乡村医生,1999,15(3):20-21.
-
2韩培英,刘金阁,郭登洲,魏素敏,都艳洁.灯盏细辛与黄芪注射液合用治疗难治性心力衰竭的临床观察[J].中西医结合心脑血管病杂志,2005,3(1):79-80. 被引量：1
-
3刘顺发,秦霞,石广念,许祖年.影响奎的平疗效的相关因素分析[J].柳州医学,2004,17(3):74-76.
-
4冀伟.阿立哌唑与利培酮治疗女性精神分裂症对照研究[J].精神医学杂志,2015,28(1):51-53. 被引量：5
-
5赵红,张青.丁咯地尔治疗脑梗塞27例临床疗效[J].中华医学写作杂志,2003,10(9):811-811.
-
6何金侠.硝普钠联合多巴胺治疗顽固性心力衰竭的临床观察[J].山西医药杂志（下半月）,2010,39(1):49-50. 被引量：5
-
7徐少卿,郭云莉.纳络酮治疗肝性脑病的临床研究[J].临床肝胆病杂志,2008,24(4):289-290. 被引量：2
-
8赵贵芳,张卫华,石玉兰,林涛.影响维思通疗效的相关因素分析[J].上海精神医学,1999,11(4):199-203. 被引量：5
-
9曹莉.巯甲丙脯酸不良反应45例分析[J].中华医学写作杂志,2001,8(6):666-667.
-
10席妹景,常秀红,张俊豪.脑卒中后癫57例临床分析[J].卒中与神经疾病,2014,21(1):53-54. 被引量：7
